Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial

• Egile Nagusiak: Deepa Joshi (Egilea), Prashant Jamadarkhana (Egilea), Suchit Kumbhare (Egilea), Amarinder Singh (Egilea), Jignesh Kotecha (Egilea), Deepak Bunger (Egilea), Ajay Shiwalkar (Egilea), Anookh Mohanan (Egilea), Chaitanya Dutt (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

TRC150094, a novel mitochondrial modulator, can restore metabolic flexibility by improving insulin resistance in preclinical studies. This study primarily aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of oral TRC150094 after conducting two double-blind, randomized, Phase-I stu...